| Primary information |
|---|
| sequence ID | Seq_3944 |
| Peptide sequence | ITHRIHWESASLL |
| CancerPDF_ID | CancerPDF_ID28, CancerPDF_ID1044, CancerPDF_ID10199, CancerPDF_ID12703, |
| PMID | 16896061,16395409,21805675,27058005 |
| Protein Name | Complement C3f,Complement C3f,Complement C3,Complement C3 |
| UniprotKB Entry Name | CO3_HUMAN,CO3_HUMAN,CO3_HUMAN,CO3_HUMAN |
| Fluid | Serum,Serum,Urine,Serum |
| M/Z | 1562.84,1562.84,1562.8365,1562.888 |
| Charge | 1,1,NA,NA |
| Mass (in Da) | 1562.84,NA,NA,NA |
| fdr | NA,NA,NA,NA |
| Profiling Technique | MALDI-TOF,MALDI-TOF,MALDI-TOF,MALDI-TOF |
| Peptide Identification technique | Q/TOF MS/MS,Q/TOF/TOF and LC-MS/MS,MALDI-TOF-MS,LC-MS/MS |
| Quantification Technique | NA,NA,NA,NA |
| Labelled/Label Free | Label Free,Label Free,Label Free,Label Free |
| FDR | NA,less than 1 “5,1,NA |
| CancerPDF_ID | CancerPDF_ID28, CancerPDF_ID1044, CancerPDF_ID10199, CancerPDF_ID12703, |
| p-Value | 1.00E-05,3.64E-08,NA,"less than 0.05,less than 0.05,0.203" |
| Software | MASCOT,MASCOT (v 2.0.04 for Windows),NA,Proteome Discoverer |
| Length | 13,13,13,13 |
| Cancer Type | Metastatic thyroid carcinomas,"Advanced Prostate, Breast and Bladder cancer",Muscle-invasive bladder cancer,Breast cancer |
| Database | NCBI refseq Protein Database,NCBI refseq Protein Database,SwissProt Database,SwissProt Database |
| Modification | NA,NA,NA,NA |
| Number of Patients | 40 metastatic thyroid carcinoma patients and 40 normal for training phase and 10 metastatic thyroid carcinoma and 10 normal individuals for independent validation,"Advanced prostate (n = 32), breast (n = 21), and bladder (n = 20) cancer, 33 healthy",751 bladder cancer and 127 control," 28 were diagnosed with Breast cancer, 27 remained cancer-free with BRCA carrier. Of the remaining patients, 39 were diagnosed with sporadic breast cancer (SBC), and 38 were healthy volunteers (WT)." |
| Regulation | NA,"Downregulated in cancer vs normal with Ratio of median intensity (patients/Controls) =0.79, 1.13 and 0.54 in prostate, bladder and breast cancer respectively",Differentially expressed between cancer vs normal samples,"Upregulated with the fold change of 1.30 in breast cancer vs Cancer free patients with brca mutation, Upregulated in breast cancer vs sporadic breast cancer with fold change of 1.22, Upregulated in BC vs healthy with 1.134 fold change" |
| Validation | Independent validation,Independent validation,Mann-Whitney tests and areas under receiver-operator characteristic,NA |
| Sensitivity | 95% on independent dataset,97.5% on independent validation dataset,NA,NA |
| Specificity | 95% on independent dataset,NA,NA,NA |
| Accuracy | NA,97.5 % on validation dataset,NA,NA |
| Peptide Atlas | NA |
| IEDB | 533899
|